CCEL

Cryo-Cell International, Inc. - 10-K Summary (Fiscal Year Ended Nov 30, 2009)

Business Context and Reporting Period

Cryo-Cell International, Inc. is a private family cord blood stem cell bank focused on the collection, processing, and cryogenic storage of umbilical cord blood (U-Cord) and menstrual stem cells (C'elle). The company operates a cGMP/cGTP-compliant facility in Oldsmar, Florida, and holds international licensing agreements in regions including Mexico, India, Venezuela, and Germany. As of November 30, 2009, the company stored over 200,000 specimens worldwide. The reporting period covers the fiscal year ended November 30, 2009.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of approximately $1.4 million in 2009, reversing a net loss of $726,000 in 2008. This improvement was driven by a 17% decrease in marketing and administrative expenses and a 26% decrease in cost of sales due to operational efficiencies.
• Revenue Decline: Total revenue decreased 6% to $16.3 million, primarily due to an 8% decrease in specimens processed and a 23% increase in sales discounts offered to attract clients during economic downturns. This was partially offset by a 10% increase in recurring storage fees.
• Unusual Item: The company incurred a one-time charge of approximately $697,000 for the cancellation of a long-term storage contract with Safti-Cell, Inc. This cancellation is expected to save the company approximately $3.3 million in storage expenses over the next 12 years.
• International Growth: Licensee income increased 28% to $1.33 million, driven by growth in the customer base of international affiliates in Mexico, India, and Venezuela.

Guidance, Outlook, and Risks

Outlook: Management anticipates funding future operations and capital expenditures (estimated at $500,000 for the next 12 months) through cash on hand and operating cash flows. The company expects to save significant costs following the Safti-Cell contract cancellation. Future growth depends on the market acceptance of the C'elle menstrual stem cell service and continued expansion of international licensing.

Risks and Contingencies:

• Internal Controls: Management identified a material weakness in internal controls over financial reporting related to the recording of licensee payments and deferred revenue. Remediation steps are underway but were not fully effective at year-end.
• Economic Sensitivity: The business is susceptible to deteriorating economic conditions as stem cell storage is a discretionary purchase. The company has already seen increased bad debt expense and has increased discounting.
• Regulatory Compliance: The company is subject to FDA regulations (21 CFR Part 1271) and state licensing requirements. Failure to comply could result in fines or operating restrictions.
• Warranty Liability: The company maintains a warranty program offering up to $50,000 if stored cells fail to engraft. While no claims have been made, the reserve balance was adjusted downward in 2009 based on new data.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 10% increase in recurring storage fees against the 8% decline in new specimens processed.
• Internal Control Remediation: Confirm the status of remediation efforts regarding the material weakness in recording licensee income and deferred revenue.
• Bad Debt Trends: Monitor the allowance for doubtful accounts, which increased significantly in 2009 ($489k provision) due to economic conditions.
• International Licensee Performance: Assess the collectability of receivables from foreign licensees, which comprised approximately 43% of total accounts receivable.
• Warranty Reserves: Review the assumptions used to calculate the warranty reserve, as small changes in engraftment failure rates could materially impact the liability.